egf816

Neuroblastoma

Cancer Research UKSmall moleculePhase 2/3Active

CC

47/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 32/ 100
Competitive Position: 81/ 100

Competitive context

46 Active assets in the Neuroblastoma cohort.

Asset / Sponsor	Phase	Rating
ETOPOSIDE M.D. Anderson Cancer Center	Phase 2/3	BB
FILGRASTIM M.D. Anderson Cancer Center	Phase 4	BB
Cyclophosphamide Robbie Majzner	Phase 2	BB
Gm-Csf Xinhua Hospital, Shanghai Jiao Tong University School of Medicine	Phase 4	BB
Evomela M.D. Anderson Cancer Center	Phase 2/3	BB

View all 50 →

Same molecule, other indications

egf816 is also rated in:

Carcinoma, Non-Small-Cell LungDormant

CCC

Indicative ·

52 / 100

non-small cell lung carcinomaDormant

CCC

Indicative ·

49 / 100

non-small cell lung carcinomaDormant

CCC

Indicative ·

49 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.